| scholarly article | Q13442814 |
| P50 | author | Deanna M. Barch | Q24580798 |
| P2093 | author name string | Cameron S Carter | |
| CNTRICS Executive Committee | |||
| P2860 | cites work | A process-oriented approach for averting confounds resulting from general performance deficiencies in schizophrenia. | Q34191198 |
| Demonstrating specific cognitive deficits: a psychometric perspective | Q34191221 | ||
| Identification of separable cognitive factors in schizophrenia | Q35942326 | ||
| Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative | Q36961097 | ||
| Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in | Q40390549 | ||
| What are the functional consequences of neurocognitive deficits in schizophrenia? | Q40976267 | ||
| The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. | Q50651673 | ||
| Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. | Q50679599 | ||
| The measurement of differential deficit | Q51282382 | ||
| Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. | Q51935852 | ||
| Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. | Q51946922 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| cognitive neuroscience | Q1138951 | ||
| P304 | page(s) | 613-618 | |
| P577 | publication date | 2008-05-21 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative | |
| P478 | volume | 34 |
| Q97066605 | Advances in the computational understanding of mental illness |
| Q30439296 | Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults |
| Q33384618 | CNTRICS final task selection: social cognitive and affective neuroscience-based measures |
| Q37100378 | CNTRICS final task selection: working memory. |
| Q33884990 | Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders |
| Q36515238 | Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. |
| Q33610028 | Factor structure of the neurocognitive tests: an application of the confirmative factor analysis in stabilized schizophrenia patients |
| Q37384503 | Genes, cognition and brain through a COMT lens |
| Q36534198 | Genetic architecture of declarative memory: implications for complex illnesses |
| Q37924021 | Genetic influence on the working memory circuitry: behavior, structure, function and extensions to illness |
| Q37662401 | Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models |
| Q35632516 | Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: Biomarkers recommended for further development |
| Q28084519 | Investigating the mechanism(s) underlying switching between states in bipolar disorder |
| Q47932815 | Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat. |
| Q35632494 | Optimization of a goal maintenance task for use in clinical applications |
| Q37259258 | Recent advances in treating cognitive impairment in schizophrenia |
| Q37100367 | Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting |
| Q30474007 | Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males |
| Q39042678 | The Five-Choice Continuous Performance Task (5C-CPT): A Cross-Species Relevant Paradigm for Assessment of Vigilance and Response Inhibition in Rodents. |
| Q91938816 | The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures |
| Q48187941 | The reliability paradox: Why robust cognitive tasks do not produce reliable individual differences. |
| Q26801568 | Translational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in Schizophrenia |
Search more.